{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:06:33Z","timestamp":1747641993822},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":741,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1093\/annonc\/mdx632","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T19:19:06Z","timestamp":1507144746000},"page":"2913-2914","source":"Crossref","is-referenced-by-count":2,"title":["DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?"],"prefix":"10.1016","volume":"28","author":[{"given":"D.","family":"P\u00e1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mdx632_bb0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdx632_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/tpj.2013.25","article-title":"Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase de\ufb01ciency","volume":"13","author":"Van Staveren","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1093\/annonc\/mdx632_bb0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"JCO"},{"key":"10.1093\/annonc\/mdx632_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity \u2013 ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1093\/annonc\/mdx632_bb0030","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1093\/annonc\/mdx632_bb0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1093\/annonc\/mdx632_bb0040","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdx632_bb0045","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx632_bb0050","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14\u2009+\u20091G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1093\/annonc\/mdx632_bb0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2015.64.2546","article-title":"Is it finally time for a personalized medicine approach for fluorouracil-based therapies?","volume":"34","author":"Offer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdx632_bb0060","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1200\/JCO.2016.66.6057","article-title":"Fluorouracil and dihydropyrimidine dehydrogenase genotyping","volume":"34","author":"Magnes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdx632_bb0065","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2016.67.4374","article-title":"Reply to T. Magnes et al","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdx632_bb0070","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(15)00360-5","article-title":"DPD deficiency in patients treated with fluorouracil","volume":"16","author":"Ciccolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx632_bb0075","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/ijc.30014","article-title":"Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity","volume":"138","author":"Meulendijks","year":"2016","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdx632_bb0080","doi-asserted-by":"crossref","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx632_bb0085","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx632_bb0090","unstructured":"U. S. Food and Drug Administration: Camptosar labell; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020571s048lbl.pdf (11 October 2017, date last accessed)."},{"issue":"1","key":"10.1093\/annonc\/mdx632_bb0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bjc.2011.206","article-title":"A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil\/leucovorin as first-line treatment in advanced colorectal cancer","volume":"105","author":"Marcuello","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdx632_bb0100","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/1078-0432.CCR-16-1012","article-title":"Genotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer","volume":"23","author":"Toffoli","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdx632_bb0105","first-page":"iii1","article-title":"Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype","volume":"28","author":"P\u00e1ez","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419354778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419354778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/12\/2913\/22295643\/mdx632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:11:32Z","timestamp":1624695092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419354778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0923753419354778"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx632","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}